The company is continuing with the evaluation of canakinumab in lung cancer, and is applying findings to the overall lung cancer development plan
It’s the company’s fourth manufacturing site worldwide. Others are located in the US, UK and China
This strategic collaboration will enable continued innovation in cancer care
Dupixent is the only biologic medicine to improve lung function in children aged 6 to 11 years in a randomized Phase 3 trial, supporting potential as a best-in-class option
The company reported 4% topline growth during the quarter driven by steady revenues in the Pharmaceuticals segment and robust growth in the Contract Research and Development Services (CRDS) segment
Following the pre-NDA meeting with the U.S. FDA, the companies confirmed the current efficacy and safety databases are expected to be adequate for filing with confirmed pathways for MDD and PPD
By combining Innovaccer's Data Activation Platform with HCL's robust healthcare data accelerator (hDATA) suite, organizations can enable patient-centricity, cost-optimization and compliance
The company proposes to invest up to US $ 50 million, over a period of five years, starting from FY22, to support capability development of talent and technology
Second interchangeable biosimilar product approved by agency
The division is expected to grow to over a 100-member strong team by 2022
Subscribe To Our Newsletter & Stay Updated
